|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C5orf66-AS1 |
Gene summary for C5ORF66-AS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C5orf66-AS1 | Gene ID | 101927953 |
| Gene name | esophagus epithelial intergenic associated transcript | |
| Gene Alias | C5orf66-AS1 | |
| Cytomap | 5q31.1 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 101927953 | C5orf66-AS1 | LZE20T | Human | Esophagus | ESCC | 2.75e-05 | 2.49e-01 | 0.0662 |
| 101927953 | C5orf66-AS1 | LZE22D1 | Human | Esophagus | HGIN | 3.00e-05 | 2.51e-01 | 0.0595 |
| 101927953 | C5orf66-AS1 | LZE22T | Human | Esophagus | ESCC | 6.04e-05 | 5.81e-01 | 0.068 |
| 101927953 | C5orf66-AS1 | LZE24T | Human | Esophagus | ESCC | 1.33e-48 | 1.60e+00 | 0.0596 |
| 101927953 | C5orf66-AS1 | P1T-E | Human | Esophagus | ESCC | 1.16e-18 | 1.06e+00 | 0.0875 |
| 101927953 | C5orf66-AS1 | P4T-E | Human | Esophagus | ESCC | 1.10e-47 | 1.37e+00 | 0.1323 |
| 101927953 | C5orf66-AS1 | P5T-E | Human | Esophagus | ESCC | 5.31e-03 | 4.10e-02 | 0.1327 |
| 101927953 | C5orf66-AS1 | P10T-E | Human | Esophagus | ESCC | 1.28e-33 | 7.87e-01 | 0.116 |
| 101927953 | C5orf66-AS1 | P12T-E | Human | Esophagus | ESCC | 1.95e-48 | 1.09e+00 | 0.1122 |
| 101927953 | C5orf66-AS1 | P15T-E | Human | Esophagus | ESCC | 1.30e-02 | -1.73e-02 | 0.1149 |
| 101927953 | C5orf66-AS1 | P20T-E | Human | Esophagus | ESCC | 6.03e-36 | 1.04e+00 | 0.1124 |
| 101927953 | C5orf66-AS1 | P21T-E | Human | Esophagus | ESCC | 9.92e-20 | 4.32e-01 | 0.1617 |
| 101927953 | C5orf66-AS1 | P23T-E | Human | Esophagus | ESCC | 2.14e-40 | 1.22e+00 | 0.108 |
| 101927953 | C5orf66-AS1 | P26T-E | Human | Esophagus | ESCC | 1.83e-20 | 6.27e-01 | 0.1276 |
| 101927953 | C5orf66-AS1 | P27T-E | Human | Esophagus | ESCC | 9.83e-58 | 1.20e+00 | 0.1055 |
| 101927953 | C5orf66-AS1 | P31T-E | Human | Esophagus | ESCC | 1.88e-03 | 4.17e-01 | 0.1251 |
| 101927953 | C5orf66-AS1 | P32T-E | Human | Esophagus | ESCC | 3.27e-02 | -2.13e-02 | 0.1666 |
| 101927953 | C5orf66-AS1 | P36T-E | Human | Esophagus | ESCC | 6.91e-06 | 2.36e-01 | 0.1187 |
| 101927953 | C5orf66-AS1 | P37T-E | Human | Esophagus | ESCC | 1.56e-03 | 3.14e-02 | 0.1371 |
| 101927953 | C5orf66-AS1 | P39T-E | Human | Esophagus | ESCC | 3.10e-22 | 5.60e-01 | 0.0894 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |